Antibodies as cancer immunotherapy

Devalingam Mahalingam; Tyler J. Curiel

doi:10.1007/978-1-4614-4732-0_11

Antibodies as cancer immunotherapy

Devalingam Mahalingam, Tyler J. Curiel^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Chapter in Book/Report/Conference proceeding › Chapter

3 Scopus citations

Abstract

Infused antibodies are the most successful immune-based agents to treat certain cancers. However, their modes of action are not always dependent on immune mechanisms aside from antigen-specific targeting. Immune mechanisms include direct and indirect cytotoxicity while nonimmune mechanisms include the targeting of toxins, such as drugs or irradiation sources, directly to the tumor, the subject of Chap. 12. Therapeutic antibodies can be chimeric or humanized (part human and part animal, usually mouse), but fully human antibodies are in trials or have been FDA approved. This chapter will summarize the current FDA-approved antibodies to treat cancer, and highlight promising antibodies in development.

Original language	English (US)
Title of host publication	Cancer Immunotherapy
Subtitle of host publication	Paradigms, Practice and Promise
Publisher	Springer New York
Pages	335-376
Number of pages	42
Volume	9781461447320
ISBN (Electronic)	9781461447320
ISBN (Print)	1461447313, 9781461447313
DOIs	https://doi.org/10.1007/978-1-4614-4732-0_11
State	Published - May 1 2013

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-1-4614-4732-0_11

Cite this

@inbook{90ef836ca8244685a6615b07f8f6f432,

title = "Antibodies as cancer immunotherapy",

abstract = "Infused antibodies are the most successful immune-based agents to treat certain cancers. However, their modes of action are not always dependent on immune mechanisms aside from antigen-specific targeting. Immune mechanisms include direct and indirect cytotoxicity while nonimmune mechanisms include the targeting of toxins, such as drugs or irradiation sources, directly to the tumor, the subject of Chap. 12. Therapeutic antibodies can be chimeric or humanized (part human and part animal, usually mouse), but fully human antibodies are in trials or have been FDA approved. This chapter will summarize the current FDA-approved antibodies to treat cancer, and highlight promising antibodies in development.",

author = "Devalingam Mahalingam and Curiel, {Tyler J.}",

note = "Publisher Copyright: {\textcopyright} 2013 Springer Science+Business Media New York. All rights are reserved.",

year = "2013",

month = may,

day = "1",

doi = "10.1007/978-1-4614-4732-0_11",

language = "English (US)",

isbn = "1461447313",

volume = "9781461447320",

pages = "335--376",

booktitle = "Cancer Immunotherapy",

publisher = "Springer New York",

}

TY - CHAP

T1 - Antibodies as cancer immunotherapy

AU - Mahalingam, Devalingam

AU - Curiel, Tyler J.

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Infused antibodies are the most successful immune-based agents to treat certain cancers. However, their modes of action are not always dependent on immune mechanisms aside from antigen-specific targeting. Immune mechanisms include direct and indirect cytotoxicity while nonimmune mechanisms include the targeting of toxins, such as drugs or irradiation sources, directly to the tumor, the subject of Chap. 12. Therapeutic antibodies can be chimeric or humanized (part human and part animal, usually mouse), but fully human antibodies are in trials or have been FDA approved. This chapter will summarize the current FDA-approved antibodies to treat cancer, and highlight promising antibodies in development.

AB - Infused antibodies are the most successful immune-based agents to treat certain cancers. However, their modes of action are not always dependent on immune mechanisms aside from antigen-specific targeting. Immune mechanisms include direct and indirect cytotoxicity while nonimmune mechanisms include the targeting of toxins, such as drugs or irradiation sources, directly to the tumor, the subject of Chap. 12. Therapeutic antibodies can be chimeric or humanized (part human and part animal, usually mouse), but fully human antibodies are in trials or have been FDA approved. This chapter will summarize the current FDA-approved antibodies to treat cancer, and highlight promising antibodies in development.

UR - http://www.scopus.com/inward/record.url?scp=84949177942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949177942&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-4732-0_11

DO - 10.1007/978-1-4614-4732-0_11

M3 - Chapter

AN - SCOPUS:84949177942

SN - 1461447313

SN - 9781461447313

VL - 9781461447320

SP - 335

EP - 376

BT - Cancer Immunotherapy

PB - Springer New York

ER -

Antibodies as cancer immunotherapy

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this